血管新生抑制剂对小鼠多阶段癌变的影响
G Bergers1, K Javaherian, K M Lo
1Department of Biochemistry and Biophysics and Hormone Research Institute, University of California, San Francisco, 513 Parnassus Ave, San Francisco, CA 94143-0534, USA.
概括
针对特定癌症阶段的血管新生抑制剂是关键. 不同的抗血管性药物在预防瘤生长,干预扩张或逆转已建立的癌症方面表现出不同的有效性.
科学领域:
- 在瘤学瘤学.
- 癌症生物学 癌症生物学
- 血管新生研究研究
背景情况:
- 固体瘤需要新的血管形成 (血管新生) 才能生长和进展.
- 转基因RIP1-Tag2小鼠模型显示,在前恶性病变中出现了血管性切换,进展到侵袭性癌症.
- 了解血管生成的作用对于开发有效的癌症疗法至关重要.
研究的目的:
- 在胰腺癌模型中评估四种不同的血管生成抑制剂的疗效.
- 为了确定抗血管原药的时间是否会影响治疗结果.
- 为了比较抑制剂在癌症发展的不同阶段的影响:前恶性病变,小瘤和大癌症.
主要方法:
- 利用RIP1-Tag2转基因小鼠模型的胰腺小岛细胞致癌.
- 使用了四种血管生成抑制剂:AGM-1470,血管,BB-94和内置.
- 在三个不同的疾病阶段测试了抑制剂的有效性:预防血管转换,瘤扩张期间的干预和晚期癌症的回归.
主要成果:
- 四种血管生成抑制剂中的每一种 (AGM-1470,血管静止素,BB-94,内静止素) 都表现出独特的疗效概况.
- 抑制剂的有效性因它们被使用的癌症进展阶段而异.
- 没有一种单一的抑制剂在瘤发育的所有测试阶段具有普遍有效性.
结论:
- 当针对癌症进展的特定阶段时,抗血管性疗法可能最有效.
- 选择血管新生抑制剂及其施用时间是治疗成功的关键因素.
- 这项研究强调了瘤血管生成的动态性质及其对药物开发的影响.
相关概念视频
Mouse Models of Cancer Study
Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
Mechanism of Angiogenesis
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Mutagenicity and Carcinogenicity
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...


